Logo
x

Search category

Subscribe Now

Fast Track designation

Calliditas Receives the US FDA's Fast Track Designation for Setanaxib to Treat Primary Biliary Cholangitis

Calliditas Receives the US FDA's Fast Track Designation for Setanaxib to Treat Primary Biliary Cholangitis

  • August 9, 2021
Lysogene Receives the US FDA's Fast Track Designation for LYS-GM101 Gene Therapy to Treat GM1 Gangliosidosis

Lysogene Receives the US FDA's Fast Track Designation for LYS-GM101 Gene Therapy to Treat GM1 Gangliosidosis

  • July 9, 2021
Fulcrum Therapeutics' Losmapimod Receives the US FDA's Fast Track Designation to Treat Facioscapulohumeral Muscular Dystrophy

Fulcrum Therapeutics' Losmapimod Receives the US FDA's Fast Track Designation to Treat Facioscapulohumeral Muscular Dystrophy

  • May 13, 2021
LEXEO Therapeutics Receives the US FDA's Fast Track Designation for LX1001 to Treat APOE4 Associated Alzheimer Disease

LEXEO Therapeutics Receives the US FDA's Fast Track Designation for LX1001 to Treat APOE4 Associated Alzheimer Disease

  • April 21, 2021
Vertex's VX-880 Receives the US FDA's Fast Track Designation for T1D

Vertex's VX-880 Receives the US FDA's Fast Track Designation for T1D

  • March 11, 2021
Targovax Receives US FDA's Fast Track Designation for ONCOS-102 for Malignant Pleural Mesothelioma

Targovax Receives US FDA's Fast Track Designation for ONCOS-102 for Malignant Pleural Mesothelioma

  • February 16, 2021
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.